Citigroup upgraded shares of Catabasis Pharmaceuticals (NASDAQ:CATB) from a neutral rating to a buy rating in a report issued on Monday, November 20th. Citigroup currently has $3.00 target price on the biotechnology company’s stock.
A number of other equities research analysts also recently commented on CATB. Oppenheimer cut their price objective on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an outperform rating for the company in a research report on Tuesday, August 15th. HC Wainwright increased their price objective on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a buy rating in a research report on Monday, August 14th. Cowen restated a market perform rating and issued a $2.00 target price on shares of Catabasis Pharmaceuticals in a report on Friday, October 6th. CIBC restated an outperform rating and issued a $7.00 target price (up previously from $4.00) on shares of Catabasis Pharmaceuticals in a report on Thursday, October 5th. Finally, Zacks Investment Research upgraded Catabasis Pharmaceuticals from a hold rating to a buy rating and set a $1.75 target price for the company in a report on Thursday, November 16th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $4.82.
Shares of Catabasis Pharmaceuticals (CATB) traded up $0.03 during trading hours on Monday, hitting $1.79. The stock had a trading volume of 93,786 shares, compared to its average volume of 1,015,286. Catabasis Pharmaceuticals has a one year low of $1.08 and a one year high of $5.51.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.02. The company had revenue of $0.25 million for the quarter. sell-side analysts forecast that Catabasis Pharmaceuticals will post -1.39 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in shares of Catabasis Pharmaceuticals in the first quarter worth $106,000. Oppenheimer & Co. Inc. increased its stake in shares of Catabasis Pharmaceuticals by 33.3% in the second quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 30,000 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of Catabasis Pharmaceuticals in the second quarter worth $271,000. Finally, Wedbush Securities Inc. increased its stake in shares of Catabasis Pharmaceuticals by 2,368.6% in the third quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock worth $534,000 after acquiring an additional 241,602 shares during the last quarter. Institutional investors own 33.14% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://ledgergazette.com/2017/12/09/catabasis-pharmaceuticals-inc-catb-raised-to-buy-at-citigroup-inc.html.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.